EUVIMEDEUVIMED entdecken
Open Access

A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison

Yong Zang iD, Peter F Thall, Ying Yuan iD

Biometrics · 2024

DOI: 10.1093/biomtc/ujad022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biometrics, 2024. Verfasst von Yong Zang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Health Data Science; Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Ind…. Hauptthemen laut MEDLINE: Research Design. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A generalized phase 1-2-3 design, Gen 1-2-3, that includes all phases of clinical treatment evaluation is proposed. The design extends and modifies the design of Chapple and Thall (2019), denoted by CT. Both designs begin with a phase 1-2 trial including dose acceptability and optimality criteria, and both select an optimal dose for phase 3. The Gen 1-2-3 design has the following key differences. In stage 1, it uses phase 1-2 criteria to identify a set of candidate doses rather than 1 dose. In stage 2, which is intermediate between phase 1-2 and phase 3, it randomizes additional patients fairly among the candidate doses and an active control treatment arm and uses survival time data from both stage 1 and stage 2 patients to select an optimal dose. It then makes a Go/No Go decision of whether or not to conduct phase 3 based on the predictive probability that the selected optimal dose will provide a specified substantive improvement in survival time over the control. A simulation study shows that the Gen 1-2-3 design has desirable operating characteristics compared to the CT design and 2 conventional designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignHumansClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicComputer SimulationDose-Response Relationship, DrugProbability

Stichwörter der Autor:innen

Bayesian designcell therapydose findingphase 1-2 clinical trialphase 1-2-3 clinical trial

Autor:innen und Institutionen

  • Department of Biostatistics and Health Data Science; Center for Computational Biology and Bioinformatics, School of Medicine, Indiana University, Indianapolis, IN 46202, United States.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

ORCID-Profile: Yong Zang, Ying Yuan

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • National Institutes of Health
  • National Cancer Institute
  • NIH/NCI

Zitieren

APA

Zang, Y., Thall, P. F., & Yuan, Y. (2024). A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics. https://doi.org/10.1093/biomtc/ujad022

Vancouver

Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics. 2024. doi:10.1093/biomtc/ujad022

BibTeX
@article{Zang2024,
  author = {Zang, Yong and Thall, Peter F and Yuan, Ying},
  title = {A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison},
  journal = {Biometrics},
  year = {2024},
  doi = {10.1093/biomtc/ujad022}
}
Kostenlos starten →